These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1. Siddiqi T; Rosen ST Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456 [TBL] [Abstract][Full Text] [Related]
3. Preclinical data expected for nucleotide GS 9219. AIDS Patient Care STDS; 2007 Apr; 21(4):289-90. PubMed ID: 17506142 [No Abstract] [Full Text] [Related]
4. The era of immuno-oncology: are we there yet? Villasboas JC; Ansell SM Oncology (Williston Park); 2015 Mar; 29(3):204-5. PubMed ID: 25772457 [No Abstract] [Full Text] [Related]
5. Obinutuzumab (Gazyva) for chronic lymphocytic leukemia. Med Lett Drugs Ther; 2014 Nov; 56(1455):e114-5. PubMed ID: 25538980 [No Abstract] [Full Text] [Related]
6. Approval of obinutuzumab as a breakthrough therapy for chronic lymphocytic leukemia. Small S Clin Adv Hematol Oncol; 2013 Dec; 11(12):809-10. PubMed ID: 25016628 [No Abstract] [Full Text] [Related]
7. Obinutuzumab breaks through to FDA approval. Cancer Discov; 2014 Jan; 4(1):OF6. PubMed ID: 24402958 [TBL] [Abstract][Full Text] [Related]
8. Bendamustine (Treanda) for CLL and NHL. Med Lett Drugs Ther; 2008 Nov; 50(1299):91-2. PubMed ID: 19008789 [No Abstract] [Full Text] [Related]
9. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation. Siddiqi T; Rosen ST Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929 [TBL] [Abstract][Full Text] [Related]
10. Berlex Laboratories to market new treatment for B-CLL. Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127 [No Abstract] [Full Text] [Related]
11. Treanda approved for chronic lymphocytic leukemia. Traynor K Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722 [No Abstract] [Full Text] [Related]
12. Lymphoma researchers in search of molecular targets. Friedrich MJ J Natl Cancer Inst; 2010 Jul; 102(14):1000-1. PubMed ID: 20616351 [No Abstract] [Full Text] [Related]
14. Drug essentials. An alkylating agent for CLL and NHL. Wilkes GM Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):55-6. PubMed ID: 19856600 [No Abstract] [Full Text] [Related]
15. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Demko S; Summers J; Keegan P; Pazdur R Oncologist; 2008 Feb; 13(2):167-74. PubMed ID: 18305062 [TBL] [Abstract][Full Text] [Related]
16. 2-Chlorodeoxyadenosine, a "novel" agent in the treatment of both lymphoid and myeloid malignancies. Lauria F Haematologica; 1992; 77(6):443-5. PubMed ID: 1363233 [No Abstract] [Full Text] [Related]
18. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie TW; Kolesar JM Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042 [TBL] [Abstract][Full Text] [Related]
19. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders]. Pawelski S Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771 [TBL] [Abstract][Full Text] [Related]
20. Ofatumumab approved for advanced CLL. Traynor K Am J Health Syst Pharm; 2009 Dec; 66(23):2062. PubMed ID: 19923303 [No Abstract] [Full Text] [Related] [Next] [New Search]